FDA Brief

Warning letters Drugs

FDA warning letter to

Genlabs Corporation

High riskIssued May 12, 2022Posted Jul 19, 2022Division of Pharmaceutical Quality Operations IV

FDA warns Genlabs Corporation of Chino, California, that its OTC hand soaps are adulterated and misbranded after finding serious CGMP failures.

What happened

FDA inspected the Genlabs drug manufacturing facility from November 29 to December 1, 2021, and again on December 9, 2021. Investigators found that hand soaps were made on the same equipment as harsh industrial cleaning products, that a batch was shipped before its test results came back, that the water system used to make drugs was never validated, and that the quality unit was not doing its job. FDA also reviewed the label of FIRST STREET Dishwashing Concentrate & Antimicrobial Hand Soap and found extra dishwashing text inside the Drug Facts panel.

What FDA found

  1. The company had no adequate procedure for cleaning equipment shared with non-drug industrial products such as window cleaner and car wax, so drug products could be cross-contaminated; FDA noted this was also cited in 2017.

    21 CFR 211.67(b)
  2. A batch of antibacterial hand soap was released and shipped before the company had its microbiological result and its test result for the active ingredient chloroxylenol.

    21 CFR 211.165(a) and (b)
  3. The company did not validate or verify the test methods it used to decide whether a batch met its specifications.

    21 CFR 211.165(e)
  4. The water system used to make drug products and clean equipment was not validated, and the company could not show its manufacturing processes were validated, including how long bulk soap could be held.

    21 CFR 211.100(a)
  5. The quality control unit did not set its own roles and responsibilities, approve specifications, run change control, reconcile labels, do annual product reviews, qualify suppliers, or run a stability program since December 2013.

    21 CFR 211.22
  6. The Drug Facts panel on FIRST STREET Dishwashing Concentrate & Antimicrobial Hand Soap contained extra dishwashing and surface-cleaning statements that do not belong there, making the product misbranded.

    FD&C Act section 502(c), 21 U.S.C. 352(c); 21 CFR 201.66(d)(7)

What FDA wants

FDA tells the company to respond in writing within 15 working days describing what it has done and will do to fix each violation and prevent it from happening again, including risk assessments, a cleaning validation program, a water system remediation and validation plan, and a quality unit remediation plan. If fixes cannot be finished in that time, the company must explain the delay and give a completion schedule.

Who should pay attention

  • brands and retailers that buy private-label hand soap from this contract manufacturer
  • drugmakers that share equipment between pharmaceutical and industrial products
  • companies that rely on a contract manufacturer's water system and release testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  3. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  4. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk